Poster Presentation of SFX-01 and Trial Update

RNS Number : 2973J

Evgen Pharma PLC

04 December 2018

 

For immediate release

4 December 2018

 

Evgen Pharma plc

("Evgen" or "the Company")

Poster presentation of SFX-01 and clinical trial update

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that a trials-in-progress poster of the Company's Phase II trial of SFX-01 in metastatic breast cancer will be presented this week at the San Antonio Breast Cancer Symposium 2018 in San Antonio, Texas.

The poster, entitled STEM: SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer, will be presented in a poster session on Wednesday 5 December 2018. The poster gives the background to SFX-01 along with a description of the STEM trial including its primary and second endpoints.

After a positive interim readout, recruitment in the STEM trial concluded in July this year. The final patient on the trial will take her last dose of SFX-01 before the end of December 2018, meaning that the final readout of the trial is expected in February or March 2019.

The San Antonio Breast Cancer Symposium is on 4-8 December 2018 in San Antonio, Texas, at the Henry B. Gonzalez Convention Center. Further information is available at this link: www.sabcs.org.

A copy of the Evgen poster will be made available on the Company's website, www.evgen.com, following its presentation at the San Antonio symposium.

Enquiries:

Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com	c/o [phone]
Buchanan Mark Court, Sophie Wills, Tilly Abraham		[phone]
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney (Corporate Finance) Rob Rees (Corporate Broking)		[phone]
WG Partners LLP Nigel Barnes, Claes Spång		[phone]

Notes for editors:

About Evgen Pharma plc

Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/ 

 

END

 

 

UPDFSLFWDFASEDE